Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00298987 · ClinicalTrials.gov registry record · Phase 2
A Study of Dasatinib in Patients With Chronic Myelogenous Leukemia Who Are Resistant or Intolerant of Imatinib Mesylate
A Phase 2 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 2
- Development phase
- 400
- Enrollment target
NCT00298987: Completed Phase 2 study, sponsored by Bristol-Myers Squibb.
NCT00298987 is a Phase 2 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 400 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (201% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00298987, a Phase 2 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 400 participants
- Enrollment target
Study Summary
The purpose of this clinical research study is to provide dasatinib treatment to patients with advanced chronic myelogenous leukemia (CML) or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) who no longer can tolerate treatment with imatinib. The safety of the treatment will also be studied.
Interventions
- DRUG Dasatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2006-02 |
| Est. Completion | 2007-06 |
| Phase | Phase 2 |
What the finished NCT00298987 record still lists
NCT00298987 is an interventional study that assigns participants to a tested intervention. The registered 400 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (201% higher).
The record links to 0 conditions, and to 1 intervention - of which Dasatinib is the first listed.
NCT00298987 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00298987 about?
NCT00298987 is a clinical study titled "A Study of Dasatinib in Patients With Chronic Myelogenous Leukemia Who Are Resistant or Intolerant of Imatinib Mesylate". The purpose of this clinical research study is to provide dasatinib treatment to patients with advanced chronic myelogenous leukemia (CML) or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) who no longer can tolerate treatment with imatinib. The safety of the treatment will a...
What is the current status of trial NCT00298987?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 400 participants. The study started on 2006-02. Estimated completion is 2007-06.
What interventions are being tested in trial NCT00298987?
The interventions under investigation include: Dasatinib (DRUG).
Who is sponsoring clinical trial NCT00298987?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00298987's enrollment target sits among peer trials
400 96th of 2000 higher than 1,898 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01665326 · 400 participants
Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease
- NCT02108054 · 400 participants · NA
Behavioral and Functional Task Development, Implementation, and Testing
- NCT02216500 · 400 participants · NA
Ketogenic Therapy Effects on Electrical and Metabolic Abnormalities in Epilepsy
- NCT02250352 · 400 participants
Core Biopsies for Establishing a Breast Tumor Tissue Repository
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia